|
Sun, 12/19/2021 - 20:32 |
BioDelivery Sciences Prevails in BELBUCA ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 |
|
Sun, 12/19/2021 - 19:14 |
More events are coming soon. |
|
Wed, 10/20/2021 - 19:15 |
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer |
|
Wed, 10/13/2021 - 20:58 |
BioDelivery Sciences International to Host ELYXYB Investor Day |
|
Thu, 09/02/2021 - 19:22 |
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences |
|
Mon, 03/04/2019 - 23:46 |
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer |
|
Mon, 03/04/2019 - 00:10 |
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA |
|
Mon, 01/14/2019 - 19:06 |
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference |
|
Mon, 01/14/2019 - 19:02 |
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference |
|
Mon, 01/14/2019 - 18:21 |
BioDelivery Sciences Announces Changes to its Executive Leadership Team |
|
Mon, 01/14/2019 - 18:12 |
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference |
|
Mon, 01/14/2019 - 16:52 |
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA |
|
Mon, 01/14/2019 - 16:31 |
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA |
|
Fri, 10/05/2018 - 16:41 |
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday |
|
Mon, 11/27/2017 - 05:14 |
BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary |
|
Thu, 11/16/2017 - 05:04 |
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference |
|
Thu, 10/12/2017 - 04:02 |
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva |
|
Fri, 10/06/2017 - 09:06 |
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence |
|
Tue, 09/19/2017 - 05:15 |
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference |
|
Tue, 09/12/2017 - 09:13 |
BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA and Associated Milestone Payment |
|
Thu, 09/07/2017 - 08:01 |
BioDelivery Sciences Presents Data on BELBUCA (buprenorphine) Buccal Film at the PAINWeek 2017 Conference |
|
Thu, 08/24/2017 - 08:11 |
BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference |
|
Wed, 08/23/2017 - 08:24 |
BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman |
|
Thu, 08/17/2017 - 06:50 |
BioDelivery Sciences to Present Three Posters on BELBUCA and BUNAVAIL at PAINWeek 2017 |
|
Mon, 07/31/2017 - 10:06 |
BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update |
|
Fri, 07/28/2017 - 03:57 |
BioDelivery Sciences to Host Conference Call and Webcast Reporting |
|
Wed, 07/12/2017 - 05:05 |
BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA In Canada |
|
Fri, 06/23/2017 - 11:08 |
BioDelivery Sciences Announces Health Canada Approval of BELBUCA |
|
Wed, 06/21/2017 - 10:46 |
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA and BUNAVAIL Through 2020 |
|
Thu, 06/01/2017 - 11:49 |
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference |
|
Wed, 11/05/2014 - 19:00 |
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials |
|
Thu, 08/07/2014 - 18:04 |
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials |
|
Mon, 07/07/2014 - 05:21 |
ENDO AND BIODELIVERY SCIENCES ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE PHASE III CLINICAL TRIAL OF BEMA BUPRENORPHINE |
